APA Daily Bulletin - Day 3, 2008 - (Page 5) May 6, 2008 The Daily BULLETIN 5 Tuesday V E S T E RM A RK AWA RD L E C T URE Distinguished educator Dr. Ronald Rieder to speak today Ronald Rieder, M.D., teaches. That’s the most concise way to summarize the career of this expert educator who has been sharing his expertise with residents for decades. For nearly 30 years, he has served as director of residency education at a premier academic institution — first at Columbia University and then Mount Sinai School of Medicine, where he teaches today. In recognition of his many years of contributing to the future of the profession, Dr. Rieder has been awarded the 2008 APA/NIMH Vestermark Psychiatry Educator Award and will present the award lecture, “What is Wrong With Our Patients?” today from 11:00 a.m. to 12:30 p.m. in Room 146 A/B on Level One of the convention center. The APA and the National Institute of Mental Health (NIMH) have jointly sponsored this award since 1969. It is named for the late Seymour Vestermark, M.D., the first director of the NIMH psychiatry education branch. On the national level, Dr. Rieder has been president of the Association of Directors of Psychiatric Residency Training and founding chair of the Committee on Research Training of the APA. Dr. Rieder received his medical education at Harvard University and then completed his internship at Johns Hopkins University. He completed his psychiatric residency at Albert Einstein College of Medicine. Dr. Rieder then did a research fellowship in the Intramural Research Program of NIMH, working with Drs. David Rosenthal and Paul Wender. He remained at NIMH for six years as a research psychiatrist and chaired education initiatives in the intramural program and the NIH’s Foundation for Advanced Education in the Sciences. His research focused on schizophrenia, including genetic and brain imaging studies. Dr. Rieder’s research background was unusual for those involved in residency training and led to his focus on integrating neuroscience and research into the curricula for psychiatric trainees. At Columbia, he developed NIMH-funded research fellowships and medical student research programs. For residents he initiated “neurobiological formulations” that related brain imaging and neuropsychological findings to clinical symptomatology. The Vestermark Award is concerned with excellence, leadership, and creativity in the field of psychiatric education. It is given annually to a psychiatric educator for outstanding contributions to the education and development of psychiatrists. It concentrates on the field of psychiatric education in its broad context, with special emphasis on preparation of teachers, use of new educational tools, and improved teaching techniques in the field of mental health. Recent awardees include Drs. Charles Pinderhughes, Carol Nadelson, Robert Michels, Herbert Pardes, Carolyn Robinowitz, Joel Yager, Jonathan Borus, James Shore, Alan Stoudemire Leah Dickstein, Jerald Kay, Marc Galanter, Frederick Sierles, Eugene Beresin, Harold Pincus, Charles Nemeroff and Stephen Sharfstein. Realize the possibilities Military, continued from page 1 brings a unique public health approach to the management of disasters and combat mental health issues. Vietnam Veterans While the Vietnam War may have ended more than 30 years ago, for the veterans who served during the conflict, it’s never left behind. And with the United States fighting a new war with several parallels to Vietnam, many veterans are experiencing a resurgence of symptoms related to the trauma they faced those many years ago. “You never really leave something like this behind,” said Laura C. Kordon, M.D., co-chair of Issue Workshop 22, “Vietnam Veterans and the Iraq War: Is the Past Ever the Past?” The workshop begins at 9:00 a.m. today in Room 141 on Level One of the convention center. “While we may be in a new war, we still have veterans from past wars that we’re not finished treating,” Dr. Kordon said. “You never really leave this behind. You take it with you. You can take it with you in a quieter way — with less anxiety or agitation — but you never leave it behind.” Dr. Kordon said this workshop will address the unique emotional reactions and responses Vietnam veterans are having to the Iraq War — specifically how current events can trigger the past. “Many veterans are disappointed to fi nd out that it still affects them,” she said. Dr. Kordon said she hope this workshop raises awareness of these issues among civilian psychiatrists and encourages them to ask their veteran patients about their past experience and how the current confl ict is affecting them. Gina, 3 7 Real patient, Manager Diagnosis: bipolar disorder Last episode: mixed ■ ■ Effectively treats acute manic and mixed episodes Well-established tolerability profile ■ ■ Target 120–160 mg/day on Day 2 Initiate dosing at 80 mg/day with meals GEODON is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic symptoms. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis. GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs. GEODON has been associated with prolongation of the QTc interval. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. Patients who are at risk for significant electrolyte disturbances should have baseline measurements performed before initiating GEODON. Patients on diuretics should be monitored. As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended. Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and durationdependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely. Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. Precautions include the risk of rash, orthostatic hypotension, and seizures. The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision. In short-term schizophrenia clinical trials, 10% of GEODON-treated patients experienced a weight gain of ≥7% of body weight vs 4% for placebo. Individual results may vary. Please see brief summary of prescribing information on adjacent page. For more information, please visit www.pfizerpro.com/GEODON http://www.pfizerpro.com/GEODON http://www.pfizerpro.com/GEODON
Table of Contents Feed for the Digital Edition of APA Daily Bulletin - Day 3, 2008 Contents Campus Violence Health Technology Frontiers in Science APA Daily Bulletin - Day 3, 2008 APA Daily Bulletin - Day 3, 2008 - Contents (Page 1) APA Daily Bulletin - Day 3, 2008 - Contents (Page 2) APA Daily Bulletin - Day 3, 2008 - Campus Violence (Page 3) APA Daily Bulletin - Day 3, 2008 - Health Technology (Page 4) APA Daily Bulletin - Day 3, 2008 - Health Technology (Page 5) APA Daily Bulletin - Day 3, 2008 - Health Technology (Page 6) APA Daily Bulletin - Day 3, 2008 - Health Technology (Page 7) APA Daily Bulletin - Day 3, 2008 - Frontiers in Science (Page 8)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.